198 related articles for article (PubMed ID: 26887783)
1. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
Serebruany VL; Fortmann SD; Rao SV; Tanguay JF; Lordkipanidze M; Hanley DF; Can M; Kim MH; Marciniak TA
Thromb Haemost; 2016 May; 115(5):905-10. PubMed ID: 26887783
[TBL] [Abstract][Full Text] [Related]
2. Continued vorapaxar versus withdrawed clopidogrel both on top of low dose aspirin in patients undergoing heart surgery: A call for randomized trial.
Serebruany VL; Kim MH; Golukhova E; Pya Y; Bekbossynova M; Cattaneo M; Marciniak TA
Int J Cardiol; 2016 Jul; 215():273-6. PubMed ID: 27128545
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
[TBL] [Abstract][Full Text] [Related]
4. Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Arif SA; D'Souza J; Gil M; Gim S
Am J Health Syst Pharm; 2015 Oct; 72(19):1615-22. PubMed ID: 26386102
[TBL] [Abstract][Full Text] [Related]
5. Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?
Serebruany VL; Fortmann SD; Hanley DF; Kim MH
Am J Ther; 2017; 24(2):e139-e143. PubMed ID: 28267691
[TBL] [Abstract][Full Text] [Related]
6. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
[TBL] [Abstract][Full Text] [Related]
7. The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect.
Serebruany VL; Choi SY; Kim MH
Int J Cardiol; 2016 Feb; 205():13-16. PubMed ID: 26709134
[TBL] [Abstract][Full Text] [Related]
8. Vorapaxar and optimal aspirin dose: The FDA outlook.
Serebruany VL; Fortmann SD; Kim MH
Int J Cardiol; 2016 Jan; 203():903-5. PubMed ID: 26609688
[TBL] [Abstract][Full Text] [Related]
9. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
Shinohara Y; Goto S; Doi M; Jensen P
J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
[TBL] [Abstract][Full Text] [Related]
10. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial.
Serebruany VL; Kim MH; Hanley DF
Int J Stroke; 2016 Aug; 11(6):614-7. PubMed ID: 26860124
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar (Zontivity) for prevention of thrombotic cardiovascular events.
Med Lett Drugs Ther; 2014 Sep; 56(1451):85-6. PubMed ID: 25211301
[No Abstract] [Full Text] [Related]
12. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
[TBL] [Abstract][Full Text] [Related]
13. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Storey RF; Kotha J; Smyth SS; Moliterno DJ; Rorick TL; Moccetti T; Valgimigli M; Dery JP; Cornel JH; Thomas GS; Huber K; Harrington RA; Hord E; Judge HM; Chen E; Strony J; Mahaffey KW; Tricoci P; Becker RC; Jennings LK
Thromb Haemost; 2014 May; 111(5):883-91. PubMed ID: 24402559
[TBL] [Abstract][Full Text] [Related]
14. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
Bhandari B; Mehta B
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
[TBL] [Abstract][Full Text] [Related]
15. Vorapaxar in the secondary prevention of atherothrombotic events.
Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
[TBL] [Abstract][Full Text] [Related]
16. The FDA report on vorapaxar in the elderly: A convoluted dilemma.
Serebruany VL; Fortmann SD
Int J Cardiol; 2015 Dec; 201():601-3. PubMed ID: 26340124
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
Morrow DA; Alberts MJ; Mohr JP; Ameriso SF; Bonaca MP; Goto S; Hankey GJ; Murphy SA; Scirica BM; Braunwald E;
Stroke; 2013 Mar; 44(3):691-8. PubMed ID: 23396280
[TBL] [Abstract][Full Text] [Related]
18. Should the Dose of Antiplatelet Drugs Be Adjusted for Body Weight? The Example of Vorapaxar.
Serebruany VL; Fortmann SD; Kim MH
Cardiology; 2016; 133(2):69-72. PubMed ID: 26488178
[TBL] [Abstract][Full Text] [Related]
19. Vorapaxar in atherosclerotic disease management.
Cheng JW; Colucci V; Howard PA; Nappi JM; Spinler SA
Ann Pharmacother; 2015 May; 49(5):599-606. PubMed ID: 25680760
[TBL] [Abstract][Full Text] [Related]
20. Vorapaxar for secondary stroke prevention: perspectives and obstacles.
Serebruany VL; Kim MH; Fortmann SD; Hanley DF
Expert Rev Neurother; 2015; 15(12):1377-82. PubMed ID: 26566105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
